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Chronic hepatitis C virus infection can cause chronic liver disease, cirrhosis and liver cancer. The
Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was a prospective,
randomized controlled study of long-term, low-dose peginterferon therapy in patients with
advanced chronic hepatitis C who failed to respond to a previous course of optimal antiviral ther-
apy. The aim of this follow-up analysis is to describe the frequency and causes of death among this
cohort of patients. Deaths occurring during and after the HALT-C Trial were reviewed by a com-
mittee of investigators to determine the cause of death and to categorize each death as liver- or
nonliver-related and as related or not to complications of peginterferon. Rates of liver transplanta-
tion were also assessed. Over a median of 5.7 years, 122 deaths occurred among 1,050 randomized
patients (12%), of which 76 were considered liver-related (62%) and 46 nonliver-related (38%);
74 patients (7%) underwent liver transplantation. At 7 years the cumulative mortality rate was
higher in the treatment compared to the control group (20% versus 15%, P5 0.049); the primary
difference in mortality was in patients in the fibrosis compared to the cirrhosis stratum (14% ver-
sus 7%, P5 0.01); comparable differences were observed when liver transplantation was included.
Excess mortality, emerging after 3 years of treatment, was related largely to nonliver-related death;
liver-related mortality was similar in the treatment and control groups. No specific cause of death
accounted for the excess mortality and only one death was suspected to be a direct complication of
peginterferon. Conclusion: Long-term maintenance peginterferon in patients with advanced
chronic hepatitis C is associated with an excess overall mortality, which was primarily due to non-
liver-related causes among patients with bridging fibrosis. (HEPATOLOGY 2011;53:1100-1108)
H
epatitis C virus (HCV) infection is the most
important cause of chronic hepatitis in the
United States and is a major cause of mor-
bidity and mortality resulting from cirrhosis and hepa-
tocellular carcinoma (HCC).1-3 Although successful
antiviral therapy with clearance of HCV appears to
decrease the rate of progression of disease and death
from chronic hepatitis C, no known beneficial therapy
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is available currently for patients who fail to respond
to standard treatment.4 The Hepatitis C Antiviral
Long-term Treatment against Cirrhosis (HALT-C)
Trial was a large, randomized controlled trial to evalu-
ate the effects of a 3.5-year course of low-dose, main-
tenance therapy with peginterferon compared to no
therapy in retarding the progression of liver disease
and in preventing endstage liver disease, HCC, and
death in patients with advanced chronic hepatitis C
who had failed to achieve a sustained response to a
previous course of optimal antiviral therapy.5 The
HALT-C Trial was initiated in 2000 and the random-
ized treatment phase completed in 2007. The results
of the randomized phase showed the lack of a benefi-
cial effect of long-term peginterferon on clinical out-
comes or death.6 Moreover, excess mortality occurred
in the treatment group among patients with advanced
fibrosis but without cirrhosis. To investigate whether
this difference in mortality persisted with longer fol-
low-up and to evaluate its possible explanations, the
HALT-C Trial cohort was followed for an additional 3
years and analyzed for the causes of deaths.
Patients and Methods
Study Design. The design of the HALT-C Trial has
been described.5,6 Briefly, between August, 2000 and
August, 2004, patients meeting the following criteria
were enrolled at 10 clinical centers in the United States:
(1) failure to achieve a sustained virological response
with previous interferon-based therapy; (2) presence of
advanced hepatic fibrosis on liver biopsy categorized as
either fibrosis without cirrhosis (Ishak Stage 3 or 4, ‘‘fi-
brosis stratum’’) or cirrhosis (Ishak Stage 5 or 6, ‘‘cirrho-
sis stratum’’)7; (3) a history of compensated liver disease
(i.e., absence of a history of hepatic decompensation or
HCC); and (4) absence of exclusion criteria (e.g., liver
disease other than hepatitis C, uncontrolled medical or
psychiatric conditions, or interferon contraindications).
Participants in the HALT-C Trial were treated ini-
tially with peginterferon alfa-2a (180 lg subcutane-
ously weekly) and ribavirin (1,000-1,200 mg daily) in
a 24-week lead-in phase, and those who failed to clear
HCV RNA by week 20 were categorized as nonres-
ponders and were eligible for randomization to treat-
ment with half-dose, maintenance peginterferon alfa-
2a (90 lg weekly) or to an untreated control group
for 3.5 years. Patients in whom HCV RNA was unde-
tectable at week 20 were categorized as responders and
continued full-dose combination therapy for up to 48
weeks. Initial responders were eligible for randomiza-
tion into the trial if virologic breakthrough occurred
during extended therapy or relapse followed 48 weeks
of therapy. In addition, patients who were treated with
peginterferon and ribavirin outside the lead-in phase
of the HALT-C Trial were also eligible for randomiza-
tion (‘‘express’’ group) if they met criteria for nonres-
ponse, breakthrough, or relapse. This approach to
enrollment ensured that all patients had received opti-
mal therapy with peginterferon and ribavirin8,9 before
they were enrolled into this long-term trial, during
which they might not be treated.5
After randomization, patients in both groups were
seen at 3-month intervals for 3.5 years, at which point
peginterferon was discontinued in the treatment group.
Nine patients assigned to the control group were
treated ‘‘off-protocol’’ by nonstudy physicians, but they
were included as controls in our intention-to-treat
analysis. Thereafter, all patients remained untreated
and were seen at 6-month intervals. At each visit the
occurrence of clinical outcomes (which had been estab-
lished prospectively) was noted, including clinical
events and laboratory markers of hepatic decompensa-
tion, HCC, or death. Although not a primary clinical
outcome in the HALT-C Trial, liver transplantation
was included in this mortality analysis because these
patients were likely to have died in the absence of liver
transplantation. Most deaths were identified by study
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coordinators interacting with family members by way
of telephone. In addition, periodic on-line searches
were performed of the U.S. Social Security Death
Index (SSDI) (http://ssdi.rootsweb.com/), which is
generated from the U.S. Social Security Administra-
tion’s Death Master File. The SSDI was queried for
any participant with whom the study site had no con-
tact for at least 6 months. The last search of the SSDI
was conducted in October, 2009. To account for the
potential lag between date of death and report to the
SSDI, we included in our analysis deaths occurring on
or before December 31, 2008.
All deaths were reviewed by a seven-person, central
review committee consisting of HALT-C Trial investi-
gators blinded to the identity of the subject, study site,
fibrosis versus cirrhosis stratum, but not randomization
allocation (treatment or control), this information
being required to assess treatment relatedness. The
committee classified the primary cause of death into
one of 15 categories (Supporting Table 1). Further-
more, the likelihood that hepatitis C-related liver dis-
ease (‘‘liver-related’’) or that peginterferon were con-
tributing causes of death (‘‘treatment-related’’) was
assessed as ‘‘unlikely’’ (<25% likelihood), ‘‘possible’’
(25%-49% likelihood), ‘‘probable’’ (50%-75% likeli-
hood) or ‘‘highly likely’’ (>75% likelihood). Differen-
ces of opinion were resolved by discussion among the
group to achieve consensus or by majority vote. For
purposes of this analysis, when the role of hepatitis C
or treatment was judged to be unlikely or only possi-
ble (i.e., <50% likelihood), the death was categorized
as nonrelated (to hepatitis C and/or treatment),
whereas the role of hepatitis C or treatment in any
death considered probable or highly likely (50%
likelihood) was classified as related.
Data Analysis and Statistics. Statistical analyses
were performed at the Data Coordinating Center with
SAS release 9.1 (SAS Institute, Cary, NC). Time-to-
event analytic methods were used to compare survival
distributions in the groups defined by randomization
group and cirrhosis stratum at baseline. Significance
was tested with the log-rank test of equality of survival
distributions. Time-to-event was defined as the time
between randomization and date of death if before De-
cember 31, 2008 or the date the participant was last
known to be alive. Participants not known to have
died were censored at the date of last study contact or
December 31, 2008, whichever occurred first. Last
study contact included the latest of the following: last
study visit, last telephone contact, last biopsy, liver
transplantation, study outcome (excluding death), or
date of randomization. Participants who died after De-
cember 31, 2008 were censored at that date.
We report the P-value for the test of the overall hy-
pothesis of equality of survival distributions and the 7-
year cumulative death rates as a measure of the size of
the difference at the end of the observation period.
Results
Patient Characteristics. Extensive details on the
composition of the HALT-C Trial cohort have been
provided in previous publications.5,6 The 1,050
randomized patients all had chronic hepatitis C, active
viremia, and a liver biopsy showing advanced fibrosis
(n ¼ 622) or cirrhosis (n ¼ 428). Participants were
predominantly male (n ¼ 745, 71%), and half were
older than 49 years (range, 19-80, median 49 years).
Most patients were non-Hispanic white (n ¼ 812,
77%), 108 (10%) were non-Hispanic black, 107
(10%) Hispanic, and 23 (2%) were of other or mixed
ethnicity. The sample included 306 (29%) people who
reported being current smokers and 221 (21%) who
were diabetic. The overall design, numbers of patients,
and flow of patients in the treatment and control arms
at the different timepoints are shown in Fig. 1.
Mortality Rates, Overall and by Cirrhosis
Status. A total of 122 deaths occurred among 1,050
randomized patients (12%) over a median period of
5.7 years (range, 0-8 years). In addition, 74 patients
(7%) underwent liver transplantation, 10 of whom
subsequently died and were included in the total num-
ber of deaths (Table 1). 53 deaths (43%) occurred
during the randomized phase of the trial, defined as
3.8 years (3.5 years plus a 3-month window around
the final study milestone) after randomization when
patients were being treated actively with peginterferon
Table 1. Death According to Baseline Stratum and
Liver-Relatedness
Stratum Outcome Death*
Cirrhosis (n ¼ 428) Liver-related





Fibrosis (n ¼ 622) Liver-related





*Numbers in parentheses represent the patients who died after liver
transplantation.
1102 DI BISCEGLIE ET AL. HEPATOLOGY, April 2011
or followed on no therapy. The remaining 69 deaths
(57%) occurred after the conclusion of the randomized
phase when all patients were being followed but no
study treatment was offered.
More deaths occurred in patients in the cirrhosis
stratum (n ¼ 80) than the fibrosis stratum (n ¼ 42),
and the survival distributions differed significantly
(P < 0.0001, Fig. 2). Seven-year cumulative mortality
rates were more than two times higher in patients in
the cirrhosis stratum than the fibrosis stratum (27%
versus 11%), which is equivalent to average annual
death rates of 3.9% in the cirrhosis and 1.5% in the
fibrosis stratum. Similarly, the distributions of the
combined outcome of death or liver transplantation
differed significantly in the two strata (P < 0.0001),
resulting in a 7-year cumulative rate of 36%
(n ¼ 120) in the cirrhosis stratum compared to 16%
(n ¼ 66) in the fibrosis stratum.
Of the 122 deaths, 76 were categorized as liver-
related (62%) and 46 as nonliver-related (38%)
(Table 1). The majority of liver-related deaths were at-
tributable directly to complications of endstage chronic
hepatitis C or HCC; however, eight deaths (11%)
were attributed to liver disease even though other
potentially fatal medical conditions were present (e.g.,
cancer other than HCC, septicemia, influenza and
pneumonia, or accident). The proportion of liver-
related deaths was slightly higher among patients in
the cirrhosis stratum compared to those in the fibrosis
stratum, but this difference was not statistically signifi-
cant (65% versus 57%, P ¼ 0.39).
Mortality Rates by Treatment Group and Fibrosis
Stratum. Overall, as well as within each stratum, the
death rate was higher in patients in the treatment
group compared to patients in the control group (P ¼
Fig. 1. Overview of the HALT-C Trial, show-
ing flow of the patient cohort from time of
randomization, through the 3.5 years of the
randomized trial phase, and during the
extended follow-up phase showing numbers
of deaths.
Fig. 2. Cumulative rates of death by fibrosis/cirrhosis stratum in
the HALT-C Trial cohort: Kaplan-Meier analysis of 622 patients in the
fibrosis stratum (fibrosis: dotted line) versus 428 patients in the cir-
rhosis stratum (cirrhosis: solid line). The vertical line at 3.5 years
marks the end of the randomized trial phase. Test of equality of distri-
butions, P < 0.0001.
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0.049, Fig. 3). The cumulative 7-year death rate was
20% in treated and 15% in control patients. The mor-
tality rates began to separate after 3 years of therapy
and continued to separate during the 2 to 3 years of
follow-up observation after treatment.
The difference in mortality rates between patients in
the treatment and control groups was statistically sig-
nificant in the fibrosis stratum (P ¼ 0.01) but was not
significant in the cirrhosis stratum (P ¼ 0.49)
(Fig. 4A). In the fibrosis stratum, at the end of the
randomized phase (3.8 years) the cumulative mortality
rate was 5.0% in patients in the treatment group com-
pared to 1.9% in patients in the control group (P ¼
0.04).6 By 7 years these rates increased to 14% and
7%, respectively. In the cirrhosis stratum the mortality
rates in patients in the treatment and control groups
were 9.1% and 8.4% at the end of the randomized
phase6 and, during follow-up observation, increased to
28% and 26%. In the fibrosis stratum, as in the group
overall, the major separation of mortality rates
occurred after 3 years of treatment.
Death and Liver Transplantation as an End-
point. The results were similar when liver transplanta-
tion and death were combined as outcomes. Among
the 1,050 patients enrolled, 186 patients (18%) either
died or underwent liver transplantation. The rates of
death or transplantation were minimally higher in the
treated than control patients and the difference was
not statistically significant (P ¼ 0.45), with 7-year cu-
mulative rates of 25% and 24%, respectively. When
separated by fibrosis stratum, however, the differences
were statistically significant (Supporting Fig. 1). In the
fibrosis stratum the rates of death or transplantation
were significantly higher in treated compared to con-
trol patients (P ¼ 0.02), with 7-year cumulative rates
of 19% and 12%, respectively, whereas in the cirrhosis
stratum rates of death or transplantation were similar
in the two groups (P ¼ 0.46), with 7-year cumulative
rates of 34% and 39%, respectively.
Specific Causes of Death and Liver Relatedness. When
causes of death were categorized by liver-relatedness, the
excess mortality in the treatment group fibrosis stratum
was primarily from nonliver causes. Thus, rates of liver-
related deaths were similar in the treatment and the con-
trol groups (P ¼ 0.42), with 7-year cumulative liver-
related death rates of 12% and 11%, respectively. The
rates of liver-related deaths in treatment and control
groups were similar in both the fibrosis stratum (P ¼
0.21) and the cirrhosis stratum (P ¼ 0.85), although the
7-year death rates did begin to show some separation in
the fibrosis stratum (8% versus 5%) but not in the cir-
rhosis stratum (19% versus 20%, Fig. 4B). On the other
hand, nonliver-related deaths were significantly more
frequent among patients in the treatment group com-
pared to the control group (P ¼ 0.03), with 7-year cu-
mulative mortality rates of 8% and 4%, respectively.
These differences were more marked in the fibrosis stra-
tum (P ¼ 0.03) than in the cirrhosis stratum (P ¼ 0.36,
Fig. 4C). The cumulative 7-year mortality rates were
6% and 2% in the treatment and control groups, respec-
tively, in the fibrosis stratum and 12% and 8%, respec-
tively, in the cirrhosis stratum.
Causes of Nonliver-Related Deaths. Examination
of the specific causes of nonliver-related deaths failed to
identify an excess frequency of any single diagnosis or
category of diseases as a cause of death. The nonliver-
related deaths reflected a spectrum of expected condi-
tions, including non-HCC cancer as well as cardiac and
cerebrovascular disease (Table 2). The distribution of
these categories of illness appeared to be similar between
those in the fibrosis and cirrhosis strata and in treated
versus untreated patients. Cases of death resulting from
malignant neoplasms other than HCC were assessed fur-
ther in an attempt to identify a pattern (Table 3). The
distribution of cancers appeared to mirror their relative
frequencies in the general population—among the 11
patients whose deaths were attributed to cancer, four
died of lung and two of colon cancer. Among the five
deaths resulting from septicemia (two liver-related and
three not liver-related: Table 2), three occurred in
Fig. 3. Cumulative rates of death by randomization group in the
HALT-C Trial cohort: Kaplan-Meier analysis of deaths in 517 patients
randomized to the treatment group (Trt: dotted line) versus 533
patients randomized to the control group (Cntl: solid line). The vertical
line at 3.5 years marks the end of the randomized trial phase. Test of
equality of distributions: Fibrosis treatment versus control P ¼ 0.21;
Cirrhosis treatment versus control P ¼ 0.85.
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association with underlying cardiac or pulmonary dis-
ease, one in association with acute pancreatitis, and one
2 years after liver transplantation. Deaths in nine
patients were categorized as ‘‘other’’ and included
trauma (3), intoxication or overdose (2), pneumonia
and respiratory failure (2), ischemic colitis (1), and sta-
tus epilepticus (1).
Role of Peginterferon Side Effects in Excess
Mortality. Special attention was given to whether
peginterferon therapy was a direct contributing factor
or cause of death in the treatment group. Most
deaths in the treated group occurred well after pegin-
terferon was stopped, with only eight patients dying
within 2 months of receiving peginterferon (11% of
deaths in the treatment group). Independent assess-
ment identified only one death as probably peginter-
feron-related. A 52-year-old man with chronic hepa-
titis C and advanced fibrosis had an episode of severe
Staphylococcus aureus septicemia followed by multior-
gan failure and death within a week of a last injec-
tion of peginterferon and after almost 2 years of
maintenance therapy.
Fig. 4. Cumulative rates of death by fibrosis/cirrhosis stratum and randomization group in the HALT-C Trial cohort: all deaths (A), liver-related
deaths only (B), and nonliver-related deaths only (C). Kaplan-Meier analysis of deaths in 309 patients in the fibrosis stratum and treatment group (Fib
Trt), 313 patients in the fibrosis stratum and control group (Fib Cntl), 208 patients in the cirrhosis stratum and treatment group (Cirr Trt), and 220
patients in the cirrhosis stratum and control group (Cirr Cntl). The vertical line at 3.5 years marks the end of the randomized trial phase. Test of equality
of distributions: (A) Fibrosis treatment versus control P ¼ 0.01; Cirrhosis treatment versus control P ¼ 0.50. (B) Fibrosis treatment versus control P ¼
0.21; Cirrhosis treatment versus control P ¼ 0.85. (C) Fibrosis treatment versus control P ¼ 0.03; Cirrhosis treatment versus control P ¼ 0.36.
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Discussion
The overall death rate in this cohort of patients with
advanced chronic hepatitis C was remarkably high. Of
the 1,050 patients, 18% died or underwent liver trans-
plantation during a median follow-up time of 5.7 years,
and approximately two-thirds of deaths (62%) could be
attributed to endstage liver disease or HCC. Among
patients with cirrhosis at baseline, the rate of death or
liver transplantation was particularly high (7-year cumu-
lative rate 36%, annualized rate 5.2%). Among those
with fibrosis without cirrhosis at baseline, rates of all
outcomes were less frequent, and the overall rate of
death or liver transplantation was lower (7-year cumula-
tive rate 16%, annualized rate 2.2%).
Several prospective studies have shown that chronic
HCV infection is associated with an increased mortal-
ity rate,10-17 but the degree of this increase has been
difficult to ascertain.18 The mortality rates observed in
the HALT-C Trial cohort were similar to those
reported in similar cohorts from other areas of the
world. For example, in a recent systematic analysis of
natural history studies, the annual rate of death or
transplantation among patients with compensated cir-
rhosis associated with hepatitis C averaged 4.6%.19 In
comparison, the annual mortality rate among HALT-C
Trial patients in the compensated cirrhosis stratum was
3.9%, and the annual rate of death or transplantation
in this stratum was 5.2%. Although the HALT-C Trial
did not include uninfected control patients for com-
parison, the high mortality rates observed, particularly
in the cirrhosis stratum, confirm the poor outcomes
among patients with chronic hepatitis C and advanced
hepatic fibrosis.
The unique finding of higher mortality among
patients in the peginterferon-treatment group noted in
the initial report of the randomized phase of the
HALT-C Trial6 persisted when analyzed with a longer
period of follow-up, the focus of the current analysis.
An important feature of the current analysis was that
all deaths were reviewed by a central committee
blinded to the patient’s identify. A cause of death was
determined by committee consensus based on prese-
lected criteria. Because reviewers were also asked to
assess possible causality due to interferon treatment,
they could not be blinded to group assignment. Dur-
ing subsequent follow-up, the difference in death rates
between patients in the treatment and control groups
remained statistically significant and actually increased
further. This was particularly true in the noncirrhotic
fibrosis stratum, the trial subset in which increased
mortality was found to be associated with maintenance
therapy during the randomized phase.6 The difference
in mortality in the cirrhosis stratum between patients
in the treatment and control groups also increased
during extended observation but did not reach statisti-
cal significance.
Of note, the excess mortality in the treatment group
cohort did not begin to arise until 3 years into treat-
ment and continued for several years after




Treatment Control Treatment Control Totals
n 5 309 n 5 313 n 5 208 n 5 220 n 5 1,050
Liver-related deaths
Chronic liver disease 8 5 20 14 47
HCC 6 3 3 9 21
Malignant neoplasm
(not HCC)*
0 1 0 1 2
Septicemia* 1 0 1 0 2
Accidental* 0 0 0 1 1
Influenza and pneumonia* 0 0 0 1 1
Unknown* 0 0 2 0 2




5 0 2 2 9
Other 1 0 5 3 9
Accidental 2 1 1 2 6
Heart disease 2 0 2 2 6
Septicemia 3 0 0 0 3
Cerebrovascular disease 0 0 2 0 2
Influenza and pneumonia 0 1 0 0 1
Unknown 1 2 4 3 10
Totals 14 4 16 12 46
*These eight deaths were attributed to liver disease even though other poten-
tially fatal medical conditions were present.
Table 3. Malignant Neoplasms Other than HCC Causing
Death in 11 Patients
Stratum Randomization Group Diagnosis
Liver-related*
Fibrosis Control Colon cancer with liver metastases
Cirrhosis Control Lymphoma
Nonliver-related
Fibrosis Treatment Nonsmall cell lung cancer
Fibrosis Treatment Nonsmall cell lung cancer
Fibrosis Treatment Squamous cell lung cancer
Fibrosis Treatment Prostate cancer
Fibrosis Treatment Colon cancer with liver metastases
Cirrhosis Treatment Gallbladder cancer
Cirrhosis Treatment Pancreatic cancer with lung metastases
Cirrhosis Control Lung cancer
Cirrhosis Control Gastric adenocarcinoma
*Death was considered to be liver-related in these patients because, even
though they had otherwise potentially fatal nonliver diseases, the circumstances
of their deaths were most consistent with advanced liver disease, which may
have been exacerbated by treatment of the malignancies.
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peginterferon was stopped. Nevertheless, a review of
each case failed to identify an immediate or direct rela-
tionship between the increased death rate and pegin-
terferon therapy. Interferon therapy has been associated
in rare instances with fatal severe adverse events,
including suicide, acute myocardial infarction, cerebro-
vascular accident, precipitation of severe autoimmune
disease, and septicemia.20 These complications, how-
ever, did not account for the increased rate of death
associated with treatment in the HALT-C Trial cohort.
Indeed, of the 71 deaths that occurred in patients in
the treatment group, only eight occurred within 2
months of a peginterferon injection, and in only one
instance was peginterferon thought to have probably
played a contributing role (an episode of septicemia in
close temporal proximity to a peginterferon injection).
Importantly, the excess mortality in the treatment
group resulted largely from nonliver-related causes.
Indeed, rates of death attributable to endstage liver dis-
ease and HCC were similar in the treatment and con-
trol groups. Careful review of the nonliver-related
deaths, however, failed to reveal a specific disease cate-
gory associated with this excess mortality, although the
combination of death by non-HCC malignancy and
systemic infection might suggest a potential effect on
host immunity. Nevertheless, the excess mortality aris-
ing after 3 years of peginterferon treatment remains
unexplained and did not result from a specific adverse
effect of treatment or single type of fatal condition
(such as heart disease, lung disease, or cancer); the link
between treatment and mortality was both noncause-
specific and delayed. Risk factors for nonliver-related
death such as obesity and smoking were included in
the analysis but did not obviously account for the
excess deaths (data not shown).
Theoretical explanations might be offered to explain
excess mortality associated with long-term peginter-
feron treatment. Interferon-alpha is not a direct-acting
antiviral but rather acts on cell-surface receptors to
trigger signaling pathways that activate ‘‘interferon-
stimulated genes,’’ which render the cell resistant to vi-
ral infection and less capable of supporting viral repli-
cation.21,22 The basis of the antiviral activity of alpha
interferon is complex and involves multiple, often
redundant cellular pathways, such as those involved in
regeneration; cell turnover; apoptosis; and protein,
lipid, and carbohydrate metabolism. Possibly the con-
tinuous stimulation of interferon-induced genes by
long-term maintenance therapy is detrimental, particu-
larly to cells and tissues without active viral replication.
These effects may be diverse and, therefore, not mani-
fested as a single adverse reaction.
An alternative explanation for the difference in mor-
tality between the treatment and control groups in the
HALT-C Trial is the presence of an undefined con-
founding factor, such as baseline difference in the ran-
domization groups, or difference in subsequent manage-
ment. However, given the size of the trial, the success of
randomization,6 and the uniformity of management in
the two groups, these differences are unlikely to have
accounted for a statistical difference in mortality rates.
Currently, hypotheses to explain excess mortality linked
to interferon are not supported by clinical or experimen-
tal observations, but warrant further study.
Thus, the HALT-C Trial was not able to show a
benefit of long-term peginterferon maintenance on
rates of clinical progression, histologic progression to
cirrhosis, hepatic decompensation, HCC, or death.6 In
this extended follow-up analysis, as in the analysis of
the randomized trial, the mortality rate appeared to be
higher among patients in the peginterferon treatment
group. In other post-hoc analyses of the HALT-C Trial
cohort, long-term peginterferon therapy appeared to
be associated with a lower rate of late HCC, diverging
from the control group after 4 years of observation,
but only in patients with cirrhosis at baseline.23 As
shown in the current analysis, the lower rate of late
HCC was not accompanied by a lower rate of death
or liver transplantation.
In summary, long-term observation of a large cohort
of patients with chronic hepatitis C and advanced he-
patic fibrosis revealed a high rate of death, particularly
among those with cirrhosis at baseline. Approximately
two-thirds of deaths were attributable to liver disease.
An increase in mortality occurred in patients in the
long-term peginterferon treatment group, but this
increase in mortality was attributed to nonliver-related
deaths and occurred largely among patients with pre-
cirrhotic advanced fibrosis at baseline. No pattern to
this excess mortality was discernible; deaths were unre-
lated to direct effects of peginterferon treatment. These
findings suggest that the long-term use of interferon
should be evaluated cautiously and that attention to
unrelated complications is warranted.
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